Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCW702 in mCRPC
NCT04077021Phase 1Terminated
- Sponsor
- Calibr-Skaggs Institute for Innovative Medicines
- Start
- Jul 2020
- Primary completion
- Oct 2022
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of CCW702 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Calibr-Skaggs Institute for Innovative Medicines. Primary endpoints: Safety and tolerability of CCW702, Recommended Phase 2 Dose up to 2 years and 1 more. Started Jul 2020; status: terminated.
02
Drugs
CCW702
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04077021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077021.